ejpmr, 2023, 10(7), 498-508

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

EMBRACING THE FUTURE OF CLINICAL RESEARCH: UNLOCKING THE BENEFITS OF DECENTRALIZED TRIALS

***Koraganji Yamini and Kusuma Tiruveedhi**

Doctor of Pharmacy. Student at ClinoSol Research.

***Corresponding Author: Koraganji Yamini**

Doctor of Pharmacy. Student at ClinoSol Research.

Article Received on 19/05/2023 **Article Revised on 09/06/2023** **Article Accepted on 30/06/2023**

ABSTRACT

Decentralized clinical trials (DCTs) have the potential to improve accessibility, diversity, and retention in clinical trials by moving trial activities to participants homes and local surroundings. The key opportunities of decentralized trials include applying a lower participation burden, allowing underserved groups to share in Clinical trials, and getting data from the real world. In addition, regulators indicated that data collected in DCTs are expected to be more representative of the real world. The epidemic has impelled regulators to take a position on the perpetration of decentralized essentials in clinical trials, and several European national competent authorities (NCAs) have lately expressed interest in DCTs, issuing instructions and conducting DCT experimental trials To facilitate future learning, hybrid clinical trials with both on-site and decentralized elements are proposed by the respondents.

KEYWORDS: Decentralized clinical trials (DCTs), Accessibility, Diversity, Retention, Real-world data.

1. INTRODUCTION

Definition and Explanation of decentralised trials

In recent times, the elaboration of electronic data collection technology has paved the way for decentralized clinical trials (DCTs) to enter into investigation practice. The prospect of their performance goes hand in hand with the need to modernize and contemporize the applicable regulatory authorities and good clinical practice (GCP). The COVID- 19 epidemic created a strong explanation for fast- tracking the approbation of clinical trials and their perpetration in a decentralized mode, in order to ensure that they could go ahead in critical situations that demanded quick adaption of GCP procedures so as to accommodate essential investigation conditions. The description of DCTs proposed by the European Federation of Pharmaceutical Industries and Associations (EFPIA) is as follows: clinical trials that make use of digital inventions and other affiliated techniques to make them more accessible to subjects. By transferring clinical trial exertion to the party's home or to other regional settings, this minimises or eliminates physical visits to a clinical trial centre. The virtual trials may not involve personal interaction between the healthcare professionals and the participating subjects (Santoro, Eugenio, et al 2022).

Significance of decentralized trials

The multitude of terms used to describe these types of trials (e g, decentralised, remote, digital, virtual, and tele trials) indicates both the evolving nature of similar clinical trials, and the diversity of ways in which decentralisation can be applied in study. DCTs (the term that seems to be favoured by regulators) tend to mix conventional and digitally eased approaches. The type and nature of similar forms is briskly expanding as digital tools (e g, digital content, virtual consultations, the use of digital reporting platforms, digitally acquired endpoints, apps, and wearable technologies) prove acutely suitable to replace principles of traditional clinical trials. The growing interest in DCTs by sponsors and regulatory authorities is justified for several reasons. DCTs can promote higher inclusivity, diversity, and indifferent access to study participation by removing the obstacles associated with the need for propinquity to clinical sites. DCT's can ease recovery, drop detainments, enhance party retention, and be less expensive (Vayena E, et al 2023).

Purpose and Objective of decentralised trials

The purpose of a decentralized approach allows trial parties to take part in clinical study from anywhere, with exploration activities more integrated into their day-to-day routine.

DCT approaches may lessen party burden (e.g., journey costs and time loss), which may enhance retention and ease certain exploration that may others overly demanding under traditional clinical trial constructs.

The following objectives of Decentralized Clinical Trials design.

- Identify legal, authority, and practical barriers to conducting DCTs and.
- Identify chances to clarify and inform procedures that affect the perpetration of DCT's (Apostolaros M, et al 2020).

2. TRADITIONAL CLINICAL TRIALS Vs DECENTRALISED TRIALS

Overview of traditional clinical trial designs

The traditional clinical trial involves screening and recruitment of subjects at designated study centres which are generally located at trial sites readily accessible by clinical study staff, for illustration, within or close to primary or secondary care settings. This may enable more detailed screen assessments, especially involving clinical measures at the point of recruitment.

Limitation of traditional clinical trial designs

The participation of subjects who live or work in the vicinity, or those who are suitable to travel long distances to the recruitment centre. Consent is obtained in-person by study staff allowance, assuring that possible parties systematically understand the study aims, procedures and allegations of participation. Subjects can have a dialogue with the study staff and ask for interpretations (Aiyegbusi OL, et al 2023).

Introduction to decentralised trials as an alternate approach

The performance of digital technologies and other new approaches may help to enhance overall clinical trials (CT) conduct and could enable a new functional approach known as "decentralized clinical trials" (DCTs). DCTs are CTs in which trial conditioning are performed at parties' homes and/ or at regional medical centers. In addition to the full DCT approach, where parties don't visit the trial site at each time during the trial, hybrid CTs incorporate both decentralized and site - based elements. For abstract clarity, we use "DCTs" to relate to both full DCTs and hybrid DCTs. The illustrations of decentralized trial principles (also applied to as "remote essentials") include reclamation via social media, dispatching study medicines directly to parties, data collection through wearables, and telemedicine visits to integrate trial participation into parties' daily lives by reducing the need to physically attend on - site visits. As a result, DCTs may be less disruptive to the parties' lives, whereas allowing the reclamation of a further different party population and enriching datasets through further frequent or indeed continuing data collection in a real - world setting. The healthcare restrictions performing from the coronavirus condition 2019 (COVID - 19) epidemic catalyzed the use of decentralized essentials to assure party safety (by reducing the threat of infection. Audits have set up that, post - COVID - 19, investigators are interested in incorporating decentralized trial rudiments, and former enterprises have emphasized the obligingness of sponsors to apply DCTs. Likewise, the epidemic has impelled regulators to take a position on the perpetration of decentralized essentials in clinical trials, and several European national competent authorities (NCAs) have lately expressed interest in DCTs, issuing instructions and conducting DCT experimental trials (de Jong, A.J et al 2022).

Comparison of key differences between traditional and decentralised trials.

COMPONENTS	TRADITIONAL CLINICAL TRIALS	DECENTRALISED CLINICAL TRIALS
Informed consent (IC)	Patient educated on IC process, has understanding, and consent obtained at the study site.	Patient educated on IC process, has understanding confirmed, and consent obtained using remote technology.
Trial Recruitment	TV, Radio, and Newspaper advertisements, Physician referrals, Press releases, Fliers, Mailings, Cold calls, and the internet. For rare diseases, patient advocacy groups. Time and monetary burden for participation.	Physician referrals and targeted internet searches (e. g,. facebook, Instagram patient groups). For rare diseases, patient advocacy groups. Time and monetary burden of participation is reduced.
Site Monitoring by sponsor	A clinical trial monitor makes periodic visits to sites to review clinical trial conduct.	Remote technology used to make requested documents available and personnel available for interview.
Administration of Investigational product (IP)	All IP is administered by an HCP at any site	IP shipped directly to patient, as state law allows, or to local pharmacy, shipping conditions ensured and inventory reconciled. A patient self – administers oral, solid dosage IP. Mobile HCP administers more complex routes of administration. Site administers most complex routes of administration (e. g. Intrathecal injection)
Assessment of trial participants	All assessment occurs at trial site. This includes physical	Data collected continuously and remotely using wearable or implanted devices.

	examination, blood draws to measure biomarkers and endpoints, imaging and radiology, and collection and analysis of tissue (e. g., Tissue biopsy)	Specialized procedures (e.g., blood draw) performed by mobile HCP. More specialized procedures (e. g., Tissue biopsy, MRI) performed at local medical center.
Screening	In – person enrolment	Electronic enrolment
Treatment and follow – up	On – site treatment	Self – treatment or mobile healthcare providers
Retention	Scheduling in – person visits	Telemedicine
End of Study	After the lost in – person visit	Returning study equipment

3. KEY COMPONENTS OF DECENTRALISED TRIALS

Remote participant recruitment and engagement strategies

DCTs can address this reclamation problem in two ways. They make it easier to find eligible parties, and they encourage those parties to share by reducing the measure of time they spend traveling.

Expanding subject diversity: The other tactics like widening eligibility criteria, tapping into community-based medical centers and using patient advocacy groups.

- **Generating places in new communities:** Decentralized trial technologies can allow investigations to be conducted by conventions unaccustomed to conducting investigations. That way, subjects being caregivers can manage their study, enhancing trust and keeping clinic visits close to home. subjects reluctant to go to a major medical center can also enroll with ease.
- **Figure places around the subjects:** The old, centralized approach to study regulation was embedded in creating a trial point and also retaining subjects to the place. Now a "place" can be created between one subject and one exponent, and in some cases, the place is simply the subject's phone. Eventually, decentralization allows for hyperactive-original trials, freeing investigation to leave big medical centers and travel to where different parties feel most comfortable and are thus more likely to share. still, decentralized technology is just one piece of the riddle when it comes to expanding patient diversity.

✓ **The Future of Patient Recruitment And Diversity In Decentralized Clinical Trials:** To embrace decentralized trials, we need to balance remote monitoring with laboriously seeking out underserved subjects, giving clear communication from investigators, and supporting subjects in the communities where they live. We also need to remain apprehensive of other technologies in the industry that can work in tandem with the common thing of diversity and addition. Technologies like wearable health bias and indeed the common smartphone all have a part to play in expanding access and case care. It's our job in clinical investigation to remain open-minded and flexible as new ideas arise to make clinical trials more inclusive and party - centered, so we can approach the problem with creative results from all angles (Ryan Jones, 2021).

Remote informed consent and virtual trial site visits

The subjects assent to share in clinical investigation through the Participant Tracking System (PTrax) operation. The authorization form is automatically transferred into the case of EHR. PTrax enables the study members the capability to track the status of all parties in real time. Arranged in chronologic order, the main statuses are enrolled (i.e, after informed permission but before screening tests), accrued (i. e, after screening tests have been completed), completed (i.e, all study- related conditioning has been completed), and withdrawn. The accrued status is further distributed as active intervention (i.e, after the primary intervention has commenced) and long- term follow- up(ie, after study- related treatments and procedures are completed and cases are under follow- up). All parties are supplied with a hard replica of the authorization form. Electronic consent requires a device (e.g, tablet) and a discussion, either in the physical presence (i.e, for on- point, in- person authorization) or ever (through videotape or telephone) between the person authorized to gain permission or assent or Health Insurance Portability and Accountability Act (HIPAA) authorization from the implicit party. Neither the electronic consent nor the remote permission option is routinely granted when studies are approved by the IRB unless the study crew requests authorization from the IRB to use these options. Once approved, authorization forms can be participated electronically with parties. The process is eased by integration between PTrax and DocuSign (DocuSign, San Francisco, CA). The parties can assent by clicking the link, reviewing each expression, and marking their autographs.

The electronic option, which was presented in December 2013, has developed over time. Between December 2013 and August 2019, it was only used for assent parties at that point. In August 2019, the IRB approved remote electronic subscription, which is fulfilled with an e-mail link, and also eased by DocuSign. An improvement introduced in April 2021, allows both the party and the person carrying concurrence to electronically subscribe to the consent form. PTrax keeps track of whether parties are agreed on a point (Bharucha, Adil E et al., 2021).

Remote data collection and monitoring methods

Semi - structured interviews of 1 hour each were conducted online by a trained investigator with 1 to 3 reporters at a time. Data collection continued until no new themes were linked to new data according to the value criterion. Before the interviews, the interviewer and the ICF participated with the reporters. Because the interviews were conducted online, verbal authorization was obtained from each party before their interview. The interviews were recorded audio, transcribed accurately, and pseudonymous for further analysis. again classified openings and challenges for the associated themes. Five major themes were associated from the interview data.

i. justification of decentralized elements
ii. sponsor and investigator liabilities
iii. trial parties interests
iv. data quality; and
v. future directions (de Jong, A.J et al, 2022)

- **Key opportunities and challenges for the implementation of decentralized clinical trials as stated by the interviewees.**

Theme	Opportunities	Challenges
Justification of decentralized elements	DCT approaches can be particularly suitable for trials with chronic conditions, rare conditions, immobile parties, self - administrable IMP, lower safety threat profile, and confirmational CTs.	Rightly detailed description and reason of decentralized essentials in the protocol
Sponsor and investigator liabilities	Home health visits to insure proper oversight and findin g of safety events	• Parties are responsible for giving safety information. • Improper delegacy of tasks.
Trial parties interests	• Less travel burden • Larger geographical reach • progressive availability by retaining parties that would not typically share in a conventional CT.	• Inadequate relationship structure with party • Incapability to assess a party's capability and eligibility to participate • Increased workload for parties and investigators
Data quality	• Collection of continuous data closer to the real - world setting. • More complete data by enabling home/ telemedicine visits, and by reducing the data collection burden	• recovery of an oblique (tech - experience, adolescent) population • Difficulty interpreting large datasets • Limited confirmation of new digital outgrowth measures
future directions.	• Ease ' learning - by - doing ' through hybrid CTs • further harmonized evaluation of DCTs under the CTR	• Limited information on the effectiveness of decentralized essentials and its community to conventional CTs • Heterogenicity in the acceptance of decentralized essentials

Utilization of wearable devices and mobile (mHealth) technologies

Wearable devices are instruments that can be worn on the body, generally on or near the skin, and are equipped with detectors able to detect various physiological variables. Wearable technology includes devices that can be placed on the limbs, torso, or head similar as watches, bands, phones, spectacles, hearing aids, suits, belts, shoes, and patches that can measure various physiological parameters, which include HR, meter, BP, 02 saturation, temperature, steps traveled, calorie expenditure estimates, blood glucose levels, and UV radiation. This data can be used for physiological-affiliated exploration studies, discovery of aberrant parameters for clinical opinion or prognostic to give natural feedback to the addict, thereby assisting in monitoring, and indeed as an educational tool for promoting health and physical fitness. The internet enables health- directed wearable bias to stay connected while continuously measuring and recording data. This system is now applied to as "Connected Health.

Newer studies have aimed at early identification and forecast of seditious conditions, cancer decisions, measuring blood alcohol situations, etc. through smartphone screens. Combining deep neural network-machine knowledge technology with natural age estimation has further enhanced its feasibility and operation. In recent times, the world has seen a surge of relinquishment of wearable devices. In addition, among the middle to high- income socio- profitable demographics. A recent methodical review and meta-analysis of multiple randomized controlled trials of consumer wearable exertion trackers (CWAT) shows that they can help physical exertion in sedentary individuals who are overweight/ obese or with habitual respiratory conditions and reduce systolic blood pressure, waist circumference and low- viscosity cholesterol in individualities with type 2 diabetes mellitus and cardiovascular conditions. Wearable devices similar as smartwatches have been seen to advantage intellectual health in individuals with cognitive diseases (Patil V et al., 2022).

4. BENEFITS AND ADVANTAGES OF DECENTRALIZED TRIALS

- The possibility of enrolling subjects who are difficult to be suitable to take part in conventional

trials, because their home is a long way from a healthcare facility, or because of physical difficulties in reaching the facility. Eased access allows an advanced number of patients to be eligible for participation. This phase is specifically important, especially in investigation of rare complications and improves the representativeness and generalisability of the results.

- More accessible conditions for subjects, with lower avoidable discomfort and suffering, in particular for frail subjects.
- DCTs deal with staying times, contact with the suffering of other subjects, in some cases hospitalization, possible exposure to pathogens in medical center settings that can cause complications.
- Enhanced party convenience and reduced burden. en hanced party access and diversity
- Greater choice for the sharing subject, who can remain at home at least for part of the study procedures.
- Greater convenience for families and caregivers.
- The possibility of collecting "real- time" and "real- world data" in the subjects' usual living atmosphere and thus avoiding possible bias by performing assessments performed in ad hoc establishments.
- Enhanced real- world data collection and case – reported issues.
- The possibility of assessing endpoints is delicate to measure with conventional studies, thanks to the ways in which the data can be collected.
- Time- saving.
- Accelerated trial timelines and reduced costs.
- Possible for increased replenishment and retention rates (Petrini C et al., 2022).

5. CHALLENGES AND CONSIDERATIONS

Ethical considerations and participant privacy

Decentralized clinical trials (DCT's) offer several benefits when compared to traditional clinical trials, such as increased access to study participants, reduced burden on participants and increased efficiency. However, as with any clinical trial, ethical considerations and participants privacy must be carefully considered and addressed in DCT's.

One key ethical consideration in DCT's is informed consent. Participants must be fully informed about the risks and benefits of participating in the trial before providing their consent. In DCTs, this can be particularly challenging since participants may be located in different regions or countries, making it difficult to obtain and maintain informed consent. It is important to have a clear and concise process for obtaining informed consent, and ensuring that all participants fully understand the terms of the study.

Another important ethical consideration in DCTs is the protection of participants privacy. With decentralized data collection, participants may be asked to share some personal health information through digital platforms or devices. This information must be kept confidential and secure, and access to it should be strictly controlled. Additionally, participants should have the right to access and control their own data, including the right to withdraw their consent to share their data.

To address the ethical considerations and participants privacy, it is important to develop clear policies and protocols for DCT's. These policies should outline how informed consent will be obtained and how participants privacy will be protected. They should also include guidelines for how data will be stored, accessed, and shared, as well as how participants can access and control their own data.

Furthermore, DCTs have the potential to rapidly enroll patients from diverse geographic regions and populations during a public health crisis such as the COVID – 19 pandemic. This is particularly important for studies investigating new treatments or vaccines where recruitment needs to be done efficiently and quickly .DCTs can reduce the reliance on in – person interactions between patients and researchers, reducing the possibility of viral spread and ensuring the safety of both patients and researchers.

Overall, during the COVID – 19 pandemic, DCTs have proved useful in continuing research maintain social distancing measures. They have facilitated rapid enrolment, efficient recruitment, and helped to keep patients and researchers safe.(Vayena, Effy, et al., 2023)

Regulatory and legal considerations in different jurisdictions

Decentralized clinical trials (DCTs) offer the potential to increase patent participation and convenience, reduce costs, and accelerate the drug development process. However, conducting DCTs comes with regulatory and legal considerations that vary depending on the jurisdictions where the trials are conducted. Here are some of the regulatory and legal considerations in different jurisdictions.

s.no	country	Regulatory and legal considerations
(i)	United States	In the United states, DCTs must comply with federal regulations such as food, drug, cosmetic act (FD&C act) and the code of federal regulations (CFR). DCT sponsors must obtain approval from FDA and institutional review board (IRB) before conducting their trial. Additionally, DCT sponsors must comply with state laws such as data privacy and security laws and informed consent requirements.
(ii)	European union	The European Union (EU) General Data Protection Regulation (GDPR) applies to DCTs conducted within EU.GDPR requires that patients. Personal data is protected and that they are informed of how their data will be used. In addition, the clinical trials regulation (CTR) was implemented to harmonize the approval process for clinical trials across the EU. The CTR requires that sponsors obtain a single authorization to conduct trials across all participating EU countries.
(iii)	Canada	In Canada, DCTs must comply with Food and Drugs Act (FDA), which regulates the sales and distribution of drugs and medical devices. Sponsors must obtain approval from Health Canada and comply with Personal Information Protection and Electronics (PIPEDA), which regulates data privacy and security.
(iv)	Japan	In Japan, DCTs must comply with Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceuticals and Medical Devices Act). The PMD Act requires sponsors to obtain approval from the Ministry of Health, Labour and Protection of Personal Information (APPI), which regulates personal data handling.
(v)	China	In China, DCTs must comply with the Drug Administration Law, which regulates the development, manufacturing, and sale of drugs. Sponsors must obtain approval from the National Medical Products Administration (NMPA) and Cyber security Law, which regulates data privacy and security.

Regulatory and legal considerations around data privacy and security have become particularly important in the pandemic context. With the date being collected remotely and stores electronically, sponsors must ensure that patient data is adequately protected against Cyber security threats and unauthorized access.

In COVID – 19 pandemic, regulatory and legal considerations in DCTs have become even more important. The pandemic has led to disruptions in the traditional methods of conducting clinical trials, and the need for remote trial approaches has increased.

The COVID – 19 pandemic has high lightened the importance of regulatory and legal considerations in DCTs. Regulatory authorities have provided guidance and flexibilities to facilitate the conduct of remote trials while ensuring patient safety and data privacy. Sponsors must closely monitor regulatory developments and ensure compliance with local regulations to conduct ethical, safe and effective DCTs in the pandemic and beyond. .(Vayena, Effy, et al., 2023)

Ensuring data integrity, quality and security

Although additional data available from new remote sensors and wearables is one of the most valuable aspects of Decentralized methods. There data collection methods are more reliable and still evolving, there are many questions about which methods are reliable and how to compare the data collected in different ways. With decentralizes models, the same information might be gathered virtually and in face to face encounter within a study or even for a single patient. In some places regulators may want proof that data collected from different places is comparable and won't influence the overall outcome of the trial.

In any clinical trial information should be collected, recorded and handled in a way that allows for accurate reporting, interpretation and verification. Trial success depends on the quality and management of the collected data. Subject's privacy should be protected by the identification numbers and other methods. Patient folders should contain completed informed consent forms, screening sheets clarifying inclusion and exclusion criteria, patient's CRFs, laboratory values and records of all communication with the subject.

Data safety monitoring boards with relevant clinical expertise, completely independent of the investigators, should be available to evaluate interim data to ensure that participants are not exposed to additional risks. During COVID – 19 pandemic, participants have been hesitant of going to hospitals, therefore there designs should be pre-specified in protocols, prospectively registered and analyzed accordingly.

Addressing technological barriers and access to devices/internet

Decentralized clinical trials (DCTs) have the potential to increase the patient recruitment, reduce costs and improve the efficiency of clinical trials. However, they also present technological barriers and access to devices/internet that must be ensured to address their success.

(i)	Infrastructure	One of the major issues with DCTs is the lack of infrastructure in some areas. This includes poor internet connectivity, lack of access to smartphones or other devices, and limited healthcare infrastructure. To address these issues, sponsors should work to provide devices and connectivity to participants and work with local healthcare providers to help with study procedures.
(ii)	Security	With remote data collection, security is a major concern. The data must be collected and stored securely and participants must be assured that their privacy is protected. To do this the sponsors should carefully vet vendors and technological solutions, and ensure that all the data is encrypted and stored successfully.
(iii)	Training	Often, participants in DCTs are not familiar with technology being used, and may require training to use it effectively. Sponsors should provide comprehensive training and support to ensure that participants are comfortable with the technology and can use it properly.
(iv)	Adherence	With the remote data collection and monitoring, it can be difficult to ensure that the participants are adhering to the study protocols. Sponsors should use the automated reminders and alerts to keep participants on track and should work closely with healthcare providers to ensure that all data is collected correctly and in a timely manner.

While there are technological barriers ad access issues that must be addressed in DCTs, sponsors can take steps to mitigate these issues and ensure the success of their studies. By providing devices and connectivity, ensuring security, providing training and support and emphasizing adherence, sponsors can create a seamless and efficient DCT experience for all the participants.

Suggestions that could help overcome technological barriers and access to devices/internet is as follow;

- Providing devices with internet connectivity - donation of laptops and smartphones along with provision of internet through broadband and mobile networks.
- Creating community internet access points – community centers, libraries and schools can be converted in access points that can provide free Wi-Fi facilities to the residents.
- Developing educational resources with low-tech solutions – where internet connectivity is limited, resources can me developed that require minimal internet access like printers, interactive CDs or radio programs.
- Training individuals on digital literacy – to help overcome technological barriers, training programs can be developed to teach digital literacy skills to individual and communities.
- Providing technical support – can be provided to individuals and communities to resolve any issues that arise with their devices or internet connectivity.(Hashem, H., et el., 2020)

Training and support for investigators and study team

Training and support for investigators and study teams is vital to ensure that these trials run smoothly. Some steps that can be taken to provide adequate training and support for DCTs.

(i) Develop clear protocols and documents – Establishing clear protocols and documents for the DCT is essential to ensure that all members of the study team understand their roles and responsibilities. This can include SOPs for data collection, remote monitoring and communication

(ii) Offer comprehensive training – It is important to all the team members with comprehensive training to ensure that they are equipped with the skills and knowledge required for the DCT. This can include training on technology platforms, data collection and regulatory compliance.

(iii) Utilizing technology platforms – Technology platforms such as electronic data capture (EDC) systems, telehealth platforms and remote monitoring tools are essential for DCTs. Providing training o these platforms can help team members to use them more effectively.

(iv) Providing ongoing support – Is essential for the success of DCTs. This can include regular check-ins with study team members to answer questions and offer guidance, as well as troubleshooting support.(Coyle, J ey al., 2022)

6. CASE STUDIES AND SUCCESS STORIES

Highlighting successful examples of decentralized trials in various therapeutic areas on decentralized trials.

(i) Parkinson's disease: The Michel J. Fox Foundation launched a DCT in partnership with Clintrex LLC in 2017. The study aimed to explore the efficacy of a new treatment for Parkinson's disease. The trial has been successful, with participants remotely monitoring their health data through a mobile phone app, allowing for a more flexible and efficient method of conducting clinical trials.

(ii) Oncology: In 2018, a DCT was conducted by a pharmaceutical company Novartis for a breast cancer drug. This study brought together geographically diverse participants from countries such as USA, UK, and Canada who could communicate with the sponsor and investigators via a digital platform. This trial was successful, concluding that the drug was effective in treating breast cancer.

(iii) Rheumatoid arthritis: In 2018, Pfizer initiated a large-scale DCT on its rheumatoid arthritis drug, Xeljanz. The study enrolled participants from 12 countries and allowed them to participate in the trial from their homes, sharing sate through mobile apps. The trial resulted in the quicker patient recruitment and the data collection, offering more trial experience.

(iv) Cardiovascular disease: In 2019, researchers from the university of Ariozna launched a DCT that aimed to explore the effectiveness of a new medication in treating cardiovascular diseases, the study allowed participants to remotely share health data with the researchers, presenting a more patient-centric study.

These shows that how DCTs have been successfully utilized across different therapeutic areas, offering more flexible, efficient, and patient-friendly clinical trial experiences. (Bakker, Jessie P et al., 2019).

Discussing outcomes, lessons learned, and key findings from these studies

Decentralized clinical trials (DCTs) have been gaining momentum in recent years due to their potential benefits such as increased patient participation, improved data quality, and reduced trial costs and time. Let's discuss some successful examples of DCTs across different therapeutic areas, and their outcomes, key findings and lessons learned.

s.no	Success story of DCTs	Key Findings	Lessons Learned
(i)	Oncology: A DCT was conducted for a phase III trial of a targeted therapy in non-small cell lung cancer patients. The study utilized virtual visits, home health nurse visits, and remote monitoring devices. The trial showed that this approach improved patient retention and reduced trial timelines. It also led to patient-reported outcomes that were more comprehensive and robust as patients were able to report their symptoms more frequently.	Patients were also more comfortable with the remote approach as the need for travel decreased and the virtual nature of the study meant they had more flexibility.	Proper training and support for patients and clinicians using technology is critical in ensuring the success of the trial.
(ii)	Infectious Disease: There have been several COVID-19 studies leveraging DCTs, including one that aimed to evaluate the efficacy and safety of home-based treatments versus hospital-based treatments. The study used home-based treatments with remote monitoring and virtual visits led to a reduced need for hospitalization, re-admission rates, and lower healthcare costs.	Home-based treatments with virtual monitoring were safe and effective in treating COVID-19-positive patients. Virtual monitoring also provided timely intervention to prevent disease progression.	The trial's success was due to the close collaboration between various stakeholders, including patients, physicians, pharmaceutical companies, and technology providers.
(iii)	Neurology: A DCT was conducted for a phase III trial of a migraine drug. The study used patient-reported outcomes which involved virtual visits, electronic questionnaires, and smartphone apps. The approach improved patient participation, reduced monitoring workload, and increased cost savings.	Patient-reported outcomes are an essential part of neurology trials, and the use of digital tools can improve their accuracy and consistency.	Patient engagement and comfort with technology are crucial, and it is necessary to provide proper training for patients and clinicians to ensure remote visits are carried out successfully.

These successful DCTs demonstrated that virtual technologies, patient-reported outcomes, and home-based treatments can improve trial efficacy, safety, and reduce patient burden. (Bakker, Jessie P et al., 2019).

7. REGULATORY LANDSCAPE AND GUIDELINES

Overview of regulatory perspectives on decentralized trials

DCTs have the potential to increase patient recruitment, reduce costs, and speed up drug development. However, there are also regulatory challenges associated with DCTs. Regulatory agencies have been working to update guidelines and regulations to ensure that these trials meet safety and efficacy standards and adhere to ethical principles.

One of the main concerns with DCTs is data protection and privacy. Since data is collected remotely, regulators need to ensure that the data is secure and that patient privacy is protected. The General Data Protection Regulation (GDPR) in the European Union and the Health Information Portability and Accountability Act (HIPAA) in the United States are two of the main regulations that address these concerns.

Another regulatory issue is ensuring that DCTs adhere to Good Clinical Practice (GCP) guidelines. GCP guidelines establish ethical and scientific principles that guarantee the integrity and quality of clinical trials. In the case of DCTs, remote monitoring and data collection practices need to meet GCP standards. Regulatory agencies have also been working to ensure that patients have access to DCTs, regardless of their location or level of technical expertise. The FDA's guidance on clinical trials during the COVID-19 pandemic encourages sponsors to consider decentralized approaches when possible.

While there are regulatory challenges associated with DCTs, regulatory agencies are working towards updating guidelines and regulations to ensure that the benefits of DCTs can be realized while still adhering to ethical and scientific principles. (Gelis, Lian et al., 2023).

Regulatory guidance and considerations for implementing decentralized trials

When planning to implement decentralized clinical trials, there are several regulatory and ethical considerations that will need to be taken into account. Here are some key ones.

1. Informed Consent: Appropriate and informed consent from patients is crucial. This will involve informing patients about the nature of decentralized trials, how the research will be conducted, and what participation will entail.
2. Data Privacy and Security: Data privacy and security is a key concern for decentralized trials. As patients will often be required to submit data from their homes, hospitals or clinics, data privacy and security need to be safeguarded. This may involve implementing various technologies and processes to protect against cyberattacks and data breaches.
3. Patient Safety Monitoring: Decentralized trials may not provide the same level of face-to-face interaction and monitoring that traditional trials provide. This means that an effective patient safety monitoring plan will need to be established to ensure that risks are adequately assessed and managed.
4. Regulatory Approval: The regulatory requirements for decentralized studies may vary based on factors such as the location(s) where the trial will take place, the products under investigation and the regulatory environment in which it operates. It is essential to ensure that regulatory requirements are met.
5. Training and Support: As the conduct of decentralized trials involves remote location of patients and trial staff, it is necessary to provide effective training and support to all parties. In addition to the technology required to facilitate such trials, training should also include on best practices to enable effective data capture, handling and management.
6. Logistics and Site Selection: Site selection for decentralized trials, guidelines for sourcing and sending investigational medicinal products for distribution to remote patients, and appropriate identification of technology vendors to support the trials are important considerations to address. Also, logistics considerations for transport of study equipment and testing kits needs to be elaborated in the procedures.

Overall, the successful execution of decentralized trials will depend upon careful planning, transparent communication with regulatory authorities and patients, robust technology and effective collaboration between all stakeholders involved.

Collaborations and initiatives promoting decentralised trial adoptions

There are several collaborations and initiatives promoting the adoption of decentralized clinical trials. Here are a few noteworthy examples:

1. Decentralized Trials & Research Alliance (DTRA): DTRA is a global nonprofit coalition of life sciences organizations, healthcare providers, academic research institutions, and technology providers. Their goal is to accelerate the adoption of patient-centric, decentralized clinical research by driving education, research standards, and best practices.
2. Decentralized Clinical Trials Working Group: In 2020, the Clinical Trials Transformation Initiative (CTTI) established a working group to develop recommendations and guidance for the implementation of decentralized clinical trials. The group includes representatives from industry, government, and patient groups.
3. TransCelerate BioPharma: TransCelerate is a nonprofit organization comprised of biopharmaceutical companies working together to improve the clinical trials process. They have developed guidelines and tools for decentralized trials, such as technology assessments and risk management resources.
4. Clinical Trials Transformation Initiative (CTTI): CTTI is a public-private partnership that works to identify and promote practices that will increase the quality and efficiency of clinical trials. They have published recommendations for the use of remote consent, remote monitoring, and telemedicine in clinical trials.
5. HIMSS Blockchain and Healthcare Task Force: HIMSS is a global organization dedicated to improving healthcare through information technology. The Blockchain and Healthcare Task Force is focused on exploring the potential of blockchain technology in clinical trials, including decentralized trials.

These collaborations and initiatives are all focused on promoting patient-centric, decentralized clinical trials as a way to improve the efficiency, accessibility, and inclusivity of clinical research. (Gelis, Lian et al., 2023)

8. FUTURE DIRECTIONS AND IMPLICATIONS

Emerging technologies and their impact on decentralised trials

Decentralised trials (DCTs) and digital health technologies (DHT) are in growing traction for numerous reasons. Technologies are helping, making it easier to collect, transfer, and store electronic data. Subjects and providers are getting much more tech experience and more comfortable with telemedicine. We've seen the impact of the COVID- 19 epidemic. Travel restrictions, physical distancing cautions, and so forth made it actually delicate to start clinical trials at traditional investigation sites. Sponsors were motivated to begin doing further trial experiments, similar as informed concurrence agreements, data collection, and patient monitoring using telemedicine. And to no surprise, we're chancing that numerous clinical trial actors like to take

treatments at home or at their regional clinic, rather than to travel far distances to a traditional clinical trial site. It can be easier to engage people and keep them enrolled if they do not have the burden of a journey. In addition to convenience, DHTs can collect data much more constantly than listed trial visits, occasionally indeed continuously. These technologies also capture information during parties' routine activities, giving a perception of the effectiveness and safety of treatment in "real life. In a practical situation, DCTs can reduce time and charges in the long term, limiting or excluding the need for the finances associated with a traditional site. Though, there may be open technology and training costs.

This area will continue to grow as technology advances and people indeed become more comfortable with DHTs and remote drugs. The hybrid models will be more common, where some trial exertion will take place at clinical trial sites and others at subjects' homes or other accessible sites. (US Food and Drug Administration 2023).

9. CONCLUSION

The key opportunities of decentralized trials include applying a lower participation burden, allowing underserved groups to share in Clinical trials, and getting data from the real world. There must be assurance of medicine stability and suitable warehouse establishments in the subject's home, as well as measures to help unauthorized access, techniques to determine tampering, temperature tracing to assure applicable medicine warehouse, dosing journals to record administration of the medicine, and communication between the warehouse system and the medicine source to give timely stocks and help study interruptions. The decentralized essentials should suit the investigation problem and be easily described and justified on a case - by - case basis within the clinical trial protocol, owing to the novelty of these approaches. It was stated that a drop in trial costs would not be considered a sufficient reason for applying decentralized essentials. Dangers associated with the performance of decentralized essentials should be anticipated and alleviated.

REFERENCES

1. Santoro E, Ascione R, Festa M, Maruti I, Ravot E. Decentralized Clinical Trials: experience and examples. Tendenze, 2022 Jun; 65.
2. Vayena E, Blasimme A, Sugarman J. Decentralised clinical trials: ethical opportunities and challenges. The Lancet Digital Health, 2023 Apr 25.
3. Apostolaros M, Babaian D, Corneli A, Forrest A, Hamre G, Hewett J, Podolsky L, Popat V, Randall P. Legal, regulatory, and practical issues to consider when adopting decentralized clinical trials: recommendations from the clinical trials transformation initiative. Therapeutic innovation & regulatory science, 2020 Jul; 54: 779-87.
4. Aiyegbusi OL, Davies EH, Myles P, Williams T, Frost C, Haroon S, Hughes SE, Wilson R, McMullan C, Subramanian A, Nirantharakumar K. Digitally enabled decentralised research: opportunities to improve the efficiency of clinical trials and observational studies. BMJ evidence-based medicine, 2023 Feb 21.
5. de Jong, A.J., van Rijssel, T. I., Zuidgeest, M. G. P., van Thiel, G. J. M. W., Askin, S., Fons-Martínez, J., De Smedt, T., de Boer, A., Santa-Ana-Tellez, Y., Gardarsdottir, H., & Trials@Home Consortium. "Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective." *Clinical pharmacology and therapeutics*. Epub, 2022 May 17.
6. **Ryan Jones,** Forbes Councils Member. **Forbes Technology Council.** Jun 10, 2021.
7. Bharucha AE, Rhodes CT, Boos CM, Keller DA, Dispenzieri A, Oldenburg RP. Increased Utilization of Virtual Visits and Electronic Approaches in Clinical Research During the COVID-19 Pandemic and Thereafter. Mayo Clin Proc, 2021 Sep; 96(9).
8. Patil V, Singhal DK, Naik N, Hameed BMZ, Shah MJ, Ibrahim S, Smriti K, Chatterjee G, Kale A, Sharma A, Paul R, Chłosta P, Somani BK. Factors Affecting the Usage of Wearable Device Technology for Healthcare among Indian Adults: A Cross-Sectional Study. *Journal of Clinical Medicine*, 2022; 11(23).
9. Petrini C, Mannelli C, Riva L, Gainotti S and Gussoni G (2022) Decentralized clinical trials (DCTs): A few ethical considerations. Fpubh, 2022; 1081150.
10. US Food and Drug Administration. CDER Conversation: The Evolving Role of Decentralized Clinical Trials and Digital Health Technologies, 2023 May 2.
11. Vayena, Effy, Alessandro Blasimme, and Jeremy Sugarman. "Decentralised clinical trials: ethical opportunities and challenges." *The Lancet Digital Health*, 2023.
12. Vayena, Effy, Alessandro Blasimme, and Jeremy Sugarman. "Decentralised clinical trials: ethical opportunities and challenges." *The Lancet Digital Health*, 2023.
13. Hashem, H., Abufaraj, M., Tbakhi, A., & Sultan, I. (2020). Obstacles and considerations related to clinical trial research during the COVID-19 pandemic. *Frontiers in medicine*, *7:* 598038.
14. Coyle, J., Rogers, A., Copland, R., De Paoli, G., MacDonald, T.M., Mackenzie, I.S. and Trials@ Home Consortium, 2022. Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders. *British Journal of Clinical Pharmacology*, *88*(3): 1031-1042.
15. Bakker, Jessie P., Jennifer C. Goldsack, Michael Clarke, Andrea Coravos, Cynthia Geoghegan, Alan Godfrey, Matthew G. Heasley et al. "A systematic

review of feasibility studies promoting the use of mobile technologies in clinical research." *NPJ digital medicine*, 2019; 2: 1: 47.

16. McKinney, M.M., Weiner, B.J. and Wang, V., 2006, September. Recruiting participants to cancer prevention clinical trials: lessons from successful community oncology networks. In *Oncology nursing forum* (Vol. 33, No. 5).
17. Gelis, Lian, Isabelle Stoeckert, and Hans-Peter Podhaisky. "Digital Tools—Regulatory Considerations for Application in Clinical Trials." *Therapeutic Innovation & Regulatory Science*, 2023; 1-14.
18. Coravos A, Khozin S, Mandl KD. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. NPJ digital medicine, 2019 Mar 11; 2(1): 14.